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Introduction
Prostate cancer (PCa) progression and the development of castration-resistant prostate cancer (CRPC) remains a major issue in patients with this disease. Currently, the relationship between emerging molecular markers and disease prognosis and their potential therapeutic role remain to be elucidated. One of the most common genetic alterations in PCa relates to gene rearrangements between the androgen receptor-regulated gene TMPRSS2 (21q22.3) and other members of the ETS family member of transcription factor, commonly ERG (21q22.2). The potential prognostic value and role of ERG gene rearrangement in defining molecular subtypes of PCa has been investigated in various cohorts. [1] [2] [3] [4] [5] To date, it is suggested that ERG is associated with adverse clinical outcome mainly in non-surgical (i.e., expectant and watchful waiting) cohorts compared with surgical cohorts, where it associate with little or no prognostic value. [6] [7] [8] [9] [10] [11] [12] [13] [14] Recently, ERG protein expression assessed by immunohistochemistry has been documented as surrogate to ERG gene rearrangement. 15, 16 The androgen receptor (AR) is a known key mediator of disease progression. 17 Although androgen ablation is initially very effective treatment causing temporary tumor regression, this is usually followed by disease progression into aggressive and lethal CRPC. Recent investigations have demonstrated that one of the key mediators in driving progression to CRPC is AR reactivation and, in keeping with this, AR protein expression and increased mRNA levels. ERG and androgen receptor (aR) are known to function cooperatively in prostate cancer (PCa) progression. However, the prognostic value of combined ERG and aR expression and potential pathways are not well characterized. We assessed ERG and aR protein expression by immunohistochemistry in a cohort of 312 men with PCa diagnosed by transurethral resection of the prostate (TuRP). Patients were divided into those with no prior hormonal treatment (designated as PCa/ advPCa) vs. those with castrate-resistant PCa (CRPC) undergoing channel TuRP to relieve obstructive symptoms. The expression status was correlated with various clinical-pathological parameters. The Swedish watchful-waiting cohort was used for validation and characterization of potential gene signatures associated with ERG and aR.
Patients with combined ERG-positive/aR high expression profile demonstrated higher rates of PCa-specific mortality (PCSM) compared with patients with ERG-negative/aR low in patients with no prior treatment (n = 90, P = 0.032), but this was attenuated in the overall cohort which included the CRPC subgroup (n = 125, P = 0.096). The prognostic significance to PCSM was validated in the Swedish watchful waiting cohort in univariate (HR: 3.3; 95% CI: 1.9-5.6, P = 4.25E-5) and multivariate analysis (HR: 2; 95% CI: 0.97-4.1, P = 0.057), which included Gleason score. ERG/aR overexpression status characterized 152 genes signatures including WnT, PI3K/aKT and chemokine signaling pathways known to be deregulated in PCa.
In conclusion, combined ERG/aR overexpression signifies a class of patients at highest-risk of PCSM with specific key genetic alteration likely responsible for disease progression. The prognostic value of combined ERG/aR overexpression and its associated genes should be further investigated as potential prognostic and therapeutic targets in prostate cancer progression. The development of CRPC, involves accumulation of multiple genetic alterations leading to perturbation of several tightly interacting signaling pathways. 17 For example, it is known that AR, ERG, and PTEN genomic aberrations interplay in PCa and are responsible in part for the occurrence of CRPC. 24 For instance, PTEN loss has been associated with increased frequency of alterations in the PI3K signaling pathway. Furthermore, selective inhibition of either the PI3K or AR signaling pathways leads to activation of the other due to the relief of feedback inhibition, thereby giving rise to therapeutic resistance in treatments that target just one of these signaling pathways. 25, 26 In support, inhibiting both PI3K and AR signaling pathways achieves greater tumor regression, suggesting that combined therapeutic modalities may be required in treating CRPC. 25 Similar reciprocal interaction has been demonstrated experimentally for ERG which is under the regulation of AR activity, but ERG can in turn regulate AR to promote tumor invasion. 1, 27 It is documented that upregulation of either ERG or AR alone is not sufficient for promotion of tumor progression, 28 suggesting that multiple genetic perturbations and selective cooperation between multiple genes interact in PCa progression.
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Based on this tight interaction, we hypothesized that combined assessment of the expression status of ERG and AR in PCa may be more biologically and clinically relevant than analysis of either one alone. In this study, we investigated the prognostic significance of combined ERG/AR protein expression in a nonsurgical cohort consisting of locally advanced PCa patients diagnosed by transurethral resection of prostate (TURP) (designated as PCa/AdvPCa) and locally advanced CRPC patients treated by LH-RH (luteinizing hormone-releasing hormone) agonist, undergoing channel TURP to relieve obstructive symptoms.
Results

Study population
Mean patients' age for the overall cohort was 76.5 y (range 50.7-93.5 y) with average follow-up time of 23.45 mo (range 1.5-100.2 mo). Data in regards to disease progression in terms of time of hormonal therapy or surgical intervention to relieve symptomatic obstruction (channel TURP) as well as overall and cancer specific mortalities are recorded. A subgroup of the overall cohort (119/312 [38.14%]) of patients had received prior hormonal therapy (designated as CRPC) and the remainder of the patients (193/312 [61.86%]) received no prior hormonal therapy (designated as PCa/AdvPCa). A total of 299/312 (95.8%) and 292/312 (93.5%) patient's samples were available for ERG and AR assessment, respectively. None of the patients in the cohort had received radical prostatectomy. Table 1 demonstrates patient demographics of the subgroups analyzed. There was significant difference between the two subgroups of patients in relation to PCSM, GS and tumor volume. There was a marginal significance toward higher frequency of ERG positivity in the CRPC subgroup vs. the PCa/AdvPCa subgroup (P = 0.057). No difference was noted in AR expression distribution.
ERG and AR expression in the incidental/advanced and castration resistant prostate cancer cohorts
Due to differences in the clinical-pathologic characteristics and possible treatment-mediated alteration in ERG and AR expression and/or activity, we sought to investigate the prognostic significance of ERG and AR in the two subgroups separately. Based on individual tissue microarray (TMA) core sample expression, there was no difference in the proportion of cases with high AR expression between ERG-positive and -negative PCa in the overall patients cohort. Specifically, 59/127 (46.5%) vs. 231/429 (53.9%) of cores showed high AR expression in ERG-positive and ERG-negative TMA cores, respectively (P = 0.143). This association was marginal in the PCa/AdvPCa subgroup of patients, where 34/86 (39.5%) vs. 149/293 (50.9%) of TMA cores exhibited high AR expression in ERG-positive and -negative cases, respectively (P = 0.065). In contrast, the CRPC subgroup did not demonstrate such association ( Combined ERG and AR protein expression status in relation to prostate cancer specific mortality, overall survival and disease progression A total of 57/304 (18.7%) of patients experienced PCSM. As noted above, a significant difference existed between the PCa/ AdvPCa and CRPC subgroups (10.2% vs. 47.8%) (P < 0.001). Neither ERG nor AR expression by itself was significantly associated with higher-rate of PCSM in either the overall or any subgroup of the study cohort. In contrast, within the total cohort, patients with tumors exhibiting ERG-positive/AR high showed non-significant trend toward higher-rate of PCSM compared ], respectively) (P = 0.515). Moreover, patients with ERG-positive/high AR tumors had no significant difference in disease progression in terms of the time until additional treatments are needed for symptomatic relief (i.e., TURP for CRPC patients and hormonal therapy for PCa/AdvPCa patients) compared with patients with ERG-negative/low AR expression in either the PCa/AdvPCa (P = 0.75) or in CRPC subgroup (P = 0.29).
Identification of genes associated with ERG-positive/high AR status
To define the molecular signature of ERG-positive/AR high PCa, we utilized the publicly available Swedish GSE8402 cohort data sets. We first defined 197 genes as ERG signature, 272 genes as AR signature, and 270 as ERG/AR signature. The ERG and AR signatures had only 9 genes in common (Fig. 2) . One hundred fifty-two mostly upregulated genes were specific to the combined ERG+/high AR expression status and were designated as ERG-positive/high AR specific signature. The top 10 genes, their expression direction pattern, and known involved pathways are shown in Table 2 .
The 152 signature genes were analyzed to construct a functional protein network using the Reactome FI plug-in implemented in Cytoscape 29 ( Fig. 3) which showed these genes to be grouped into non-random highly interconnected functional modules, suggesting biologically relevant pathways that are perturbed in ERG-positive/high AR tumors. The major biological pathways deregulated in the ERG-positive/AR high PCa includes WNT, cell cycle, VEGF, and PI3K/AKT signaling pathways.
Validation of the prognostic value of the combined ERGpositive/high AR status in relation to prostate-cancer specific mortality
We utilized the Swedish cohort to validate our ERG-positive/ AR high signature, which documented significant association with poor outcome and lethal disease. Specifically, 25/26 PCa patients with ERG-positive/high AR had lethal outcome compared with 40/62 in the ERG-negative/AR low group. ERGpositive/high AR samples were significantly at higher-risk of PCSM compared with ERG-negative/AR low. HR: 3.3; 95% CI: 1.9-5.6, P = 4.25E-5 (Fig. 4) . There was no prognostic difference between tumors with ERG-negative/low AR, ERG-positive/low AR, or ERG-negative/high AR status, confirming our own data above that the concomitant expression of ERG and AR defines a higher-risk group of patients (not shown).
In multivariable analysis, ERG-positive/AR high was still marginally significant and showed better correlation with the clinical outcome (HR: 2; 95% CI: 0.97-4.1. P = 0.057) compared with either ERG (HR: 1.39; 95% CI: 0.78-2.45, P = 0.254) or AR (HR: 0.89; 95% CI: 0.62-1.27, P = 0.528) expression alone. However, it did not outperform GS ( Table 3) .
Discussion
Previous studies had shown that ERG gene rearrangements and protein expression are significantly associated with lethal PCa in none surgically treated patients. 12 ,13 AR expression and amplification have been found to play a major role in PCa progression and the development of CRPC. 30 Moreover, a strong reciprocal interaction was demonstrated experimentally between ERG and AR, 1, 27 suggesting that both cooperate functionally in PCa progression.
Although ERG-positive/AR high expression profile conferred adverse clinical outcome compared with ERG-negative/low AR tumors in our PCa/AdvPCa subgroup, this difference was attenuated when including the CRPC subgroup which may suggest that the prognostic value of the two combined markers is more relevant in tumors not initially subjected to hormonal manipulation. However, as previously documented, it is likely that ERG and AR intensity levels are altered by the prior hormonal therapy within the CRPC group. 15 Moreover, our inability to document any differences in disease progression in terms of the time until the requirement for additional therapy to relief symptoms may be reflective of the limited number of patients within each subgroup (n = 52, 23, and 31) given the higher number of overall and PCSM mortality rates noted above. Therefore, it is hypothesized that patients with ERG-positive/AR high expression profile signify a subgroup of PCa patients with higher-risk of disease progression and likely require more aggressive management.
Experimental observation from recent reports suggest that neither ERG nor AR overexpression alone is sufficient to enhance PCa progression and that both are required for disease progression. 28 Our data documenting insignificant prognostic difference in any other ERG/AR expression combination is further support of the recent in-vitro data documenting attenuation of the aggressive behavior of PCa cells by targeting the ERG, AR and WNT pathways. 31, 32 Finally, as a first step toward elucidating the mechanistic basis of this aggressive PCa molecular subtype, we defined 152 signature genes specific to ERG-positive/AR high PCa (Fig. 3) . Based on known function and interactions, these genes are grouped into non-random highly interconnected functional modules (Fig. 3) , as most of the major biological pathways involved by these genes, including WNT, 32, 33 VEGF, PTEN/PI3K/AKT/ mTOR, 24, 34 and chemokine 35 signaling pathways, have previously been implicated in various stages of PCa progression and many have been found to interact with ERG and AR. Indeed, analysis of the individual signature genes suggest that ERG and AR combined expression leads to deregulation of multiple cellular processes including, cell cycle, cell growth and differentiation, transcriptional regulation, specific protein turnover as well as intra-and extra-cellular signaling ( Table 2) . However, thus far only some of the identified genes have been studied in the context of prostate cancer biology. Notably, we have found the gene encoding a CDK2 inhibitor CDK2P1 to be upregulated as an ERG-positive/AR high gene signature. Overexpression of a CDK2AP1 had been found in one study to lead to a reduction in cellular growth in vitro using different prostate cancer cell lines. 36 However, this has not been studied in vivo and the effect of CDK2AP1 expression may be dependent on complex interaction between the cell cycle and the AR pathway since this same study also found CDK2AP1 expression to correlate positively with AR re-expression in certain cell line.
RAB3B is another ERGpositive/AR high gene signature that is upregulated. RAB3B is a member of the RAB GTPase family and is overexpressed in prostate cancer patients. Moreover, overexpression of RAB3B via a transcriptional regulatory network composing of AR and other transcription factors iNKX3-1 (NK3 homeobox 1) and FoxA1 (Forkhead box A1) has been found to promote prostate cancer cell survival. 36, 37 The reason why both putative tumor-suppressors CDK2AP1 and RAB3B are upregulated in the more aggressive ERG-positive/AR high prostate cancer in the present study is not clear. However, it is not uncommon for clinically aggressive and therapeutically resistant cancers to overexpress tumor-suppressors genes that have initially been implicated to function as tumor suppressors in vitro and in mouse xenograft models. This is illustrated in the case of the putative tumor suppressor gene Drg1 (differentiation-related gene 1), the expression of which has been associated with aggressive hepatocellular carcinoma and resistance to irinotecan chemotherapy in colorectal cancer. Other ERG-positive/AR high gene signatures are implicated in regulation of gene expression. For instance, FUBP1 (far-upstream element binding protein 1) is an upregulated ERGpositive/AR high gene signature that encodes a protein which had been found to regulate c-myc proto-oncogene transcription and to be frequently expressed in prostate cancer. 39 Although the study failed to document any association with clinic-pathological variables or c-myc protein expression, its role in prostate cancer biology remains to be elucidated since the FUBP family of proteins has been shown to bind a variety of RNAs suggesting functions other than c-myc expression regulation. 39 In conclusion, we characterize and validate a molecular subtype of prostate tumors combining ERG and AR overexpression in association to PCa progression in terms of PCa-specific as well as overall mortality. We further identifies gene signatures associated with ERG-positive/AR high expression profile and show that these can be grouped into non-random functionally interacting modules affecting pathways implicated in ERG and/or AR-mediated PCa progression. Patients with ERG-positive/AR high tumors are at higher-mortality risk and should be managed more aggressively. Our findings are in keeping with the strong cooperatively between ERG and AR in PCa and underpin the need for combined gene analysis in achieving better PCa prognostication.
Materials and Methods
Study population and tissue microarray construction
The study cohort consisted of 312 men diagnosed with PCa by TURP and managed expectantly by observation, radiotherapy or hormonal manipulation between 2005 and 2009. To assess the relation and interaction with hormonal therapy, we subdivided the cohort into two subgroups. The first (n = 193), consisted of tumors with no prior hormonal therapy, referred to asPCa/ AdvPCa. The second group represented men with CRPC (n = 119), who were initially treated by LH-RH agonist as monotherapy, but subsequently progressed to require channel TURP to relieve obstructive symptoms. Clinical follow-up was collected from the Alberta Tumour Registry in regard to overall survival, cancer-specific mortality, and dates of hormonal treatment implementation. Prostate cancer-specific mortality (PCSM) was defined as patients with evidence of metastatic disease who progressed while on hormonal therapy and died of PCa based on medical records. The complete cohort was assembled onto two tissue microarrays (TMAs) with an average of two cancer cores (2-6) per patient including adjacent benign prostate tissue as control for a total of 714 cores using a manual tissue arrayer (Beecher Instruments). Each block was assembled without prior knowledge of any clinical or pathological staging information.
All Clinical and pathological data were obtained with approval of the institutional review board at University of Calgary, Faculty of Medicine.
ERG and AR protein expression assessment by immunohistochemistry ERG immunohistochemistry was performed as previously described.
13 AR immunohistochemistry was performed on Leica Bond Max platform (Leica Microsystems). Four µm thick formalin-fixed paraffin-embedded sections were subjected to heat-induced antigen retrieval for 30 min using Leica Epitope Retrieval Solution 2. Slides were then incubated with androgen receptor mouse monoclonal antibody from Santa Cruz clone AR441 (sc-7305) for 15 min at a 1:200 dilution. Bond Polymer Refine Detection kit (Leica Microsystems) was used for HRP detection following hematoxylin counter stain. The correlation between AR gene amplification status and AR protein expression in prostate cancer as assessed by immunohistochemistry was previously demonstrated in Sicar et al. 40 
Pathological analysis
Histological diagnosis of TMA cores were confirmed by two study pathologists (SAH and TAB) on the initial slides. GS was assessed according to the 2005 ISUP criteria. 41 For each patient, the predominant two patterns of PCa were sampled. ERG immunohistochemistry was assessed as positive vs. negative based on previous correlation with ERG gene rearrangement detected by break apart fluorescent in situ hybridization assay. 15 ERG expression was strongly and consistently expressed in endothelial cells, acting as internal control. AR immunohistochemistry was categorized as high vs. other lower intensities (Fig. 5) . Specifically, the AR immunostaining intensity was graded semi-quantitatively on a grading scale of 0-3 by two pathologists who assigned a grade of 3 to the highest intensity of a given sample, grade 1 to the lowest staining intensity above faint non-specific stromal and endothelial cell staining, and grade 2 to staining intensities between grade 1 and 3. Grade 0 was assigned to those samples with staining intensity no higher than the non-specific staining in the stroma. The high AR PCa expressers were designated as those with immunostaining intensity grade 3, and the low AR PCa expressers were those with immunostaining intensity grades 0-2.
Development of ERG/AR signature
The Swedish GSE8402 cohort (n = 281) data sets was used to define a molecular signature for ERG and AR 42 (Information regarding this cohort can be accessed through the NCBI Gene Expression Omnibus site http://www.ncbi.nlm.nih.gov using the GEO accession identification number GSE8402). Forty-four samples were ERG rearranged (ERG-positive) as determined by fluorescent in situ hybridization (FISH) and 190 expressed high AR mRNA as determined by PAM clustering implemented in cluster R package. ROC area under curve was used to filter signature genes differentially expressed between ERG-positive vs. ERG-negative, high vs. low AR and ERG-positive/AR high vs.
ERG-negative/AR low PCa. AUC 0.7 was used as a threshold to filter significant genes. As a result; 152 genes were identified in the ERG-positive/AR high subgroup. The Reactome Functional Interaction plug-in in Cytoscape 29 was used to build the network between these genes to better understand the systems biology behind the combination of ERG and AR overexpression in PCa.
Statistical analysis
Patient characteristics were presented as frequencies and percentages for categorical variables, and as means and ranges for continuous variables. Chi-square test was used to test for associations between ERG and AR protein expression. The KaplanMeier approach along with the log-rank test was used for survival analyses to test associations between ERG and AR expression and each of PCSM overall mortality, and time till development of castrate resistant disease. Multivariate analysis was conducted using Cox regression models including ERG, AR and GS to associate variables to lethal disease. In all statistical tests a P value < 0.05 was considered significant.
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